Pfizer’s Strong Financial Performance and Promising Pipeline Drive Buy Rating

Nico Chen, an analyst from DBS, maintained the Buy rating on Pfizer (PFE – Research Report). The associated price target remains the same with $30.00.

Nico Chen has given his Buy rating due to a combination of factors including Pfizer’s impressive financial performance and promising product pipeline. The company’s Q4 2024 results exceeded expectations, with significant revenue growth and a return to profitability, driven by effective cost management and strong sales of COVID-related products. This financial strength is further supported by Pfizer’s guidance for 2025, which anticipates robust revenue and earnings per share.
Nico Chen also highlights the potential of Pfizer’s innovative treatments as key drivers for future growth. The clinical development of Danuglipron, an oral GLP-1 drug for diabetes and weight loss, shows promising results and is expected to advance to late-stage trials. Additionally, Pfizer’s acquisition of Seagen and its collaboration with Summit Therapeutics to develop antibody-drug conjugates (ADCs) could lead to groundbreaking treatments in oncology. These strategic initiatives are anticipated to enhance Pfizer’s market position and drive its share price upward.

In another report released on May 21, Jefferies also maintained a Buy rating on the stock with a $33.00 price target.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year.